01/06
Headlines

ICPT

Stocks in Focus: API Technologies (NASDAQ:ATNY), Intercept Pharmaceuticals (NASDAQ:ICPT), OvaScience (NASDAQ:OVAS), Charles & Colvard Ltd. (NASDAQ:CTHR)

Jayne Crisman02 mins

API Technologies Corp. (NASDAQ:ATNY), a leading provider of high performance RF/microwave, power, and security solutions for critical and high-reliability applications, announced today the launch of configurable frequency synthesizers (Models LCFS-X), the newest addition to the Company’s line of standard RF / microwave products. API Technologies Corp. (NASDAQ:ATNY) belongs to Technology sector. Its net profit margin…

Read More
Bluebirdbio BLUE NASDAQ BLUE

Healthcare Gainers: Gentiva Health Services (NASDAQ:GTIV), bluebird bio Inc (NASDAQ:BLUE), Celldex Therapeutics (NASDAQ:CLDX), Intercept Pharmaceuticals (NASDAQ:ICPT), Northwest Biotherapeutics (NASDAQ:NWBO)

Mark DeFrance04 mins

Gentiva Health Services Inc. (NASDAQ:GTIV)’s rejection of the takeover proposal from Kindred Healthcare Inc. ( KND ) is hitting headlines and drawing investor attention to the healthcare space. Gentiva Health Services, Inc. (NASDAQ:GTIV) stock performance was -1.52% in last session and finished the day at $13.62. Traded volume was 1.47million shares in the last session…

Read More

Mid Cap Volatile Stocks: Ubiquiti Networks (NASDAQ:UBNT), Qunar Cayman Islands (NASDAQ:QUNR), Criteo (NASDAQ:CRTO), Intercept Pharmaceuticals (NASDAQ:ICPT)

Colin Pettis02 mins

Stock analysts at Macquarie initiated coverage on shares of Ubiquiti Networks Inc (NASDAQ:UBNT) in a report issued on Thursday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating on the stock. Ubiquiti Networks Inc (NASDAQ:UBNT) stock performance was -10.22% in last session and finished the day at $44.18. Traded volume was 2.87million shares in the last…

Read More
FB Nasdaq FB Facebook

Healthcare Movers: Intercept Pharmaceuticals Inc. (NASDAQ:ICPT), Pernix Therapeutics (NASDAQ:PTX), Galena Biopharma (NASDAQ:GALE), Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Mark DeFrance02 mins

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) is lower after the company reported mixed Q4 and full-year 2013 earnings, as well as releasing results for its Phase 3 POISE trial. Shares are now down 10.71% at $412.75, but are still at the higher end of its 52-week range of $30.38 – $497.00 On Friday, Intercept (NASDAQ:ICPT) reported a…

Read More